Zynerba Pharmaceuticals

Dedicated to the development of innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders

Learn More

Our mission is to improve the lives of patients battling severe rare and near-rare neuropsychiatric disorders including Fragile X syndrome and certain refractory epilepsies including developmental and epileptic encephalopathies (DEE).

Our Team

Our Team

Our team has a proven track record of success in developing novel transdermal products for patients in need.

More >>

Our Development Pipeline

Our Development Pipeline

We are developing a proprietary pharmaceutically-produced transdermally-delivered CBD gel in multiple neuropsychiatric indications, including Fragile X syndrome and certain refractory epilepsies.

More >>

For Investors

For Investors

Learn more about our company and our potential.

More >>

Latest News

1108

Zynerba Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights

Learn More

1011

Zynerba Pharmaceuticals to Present at the 2018 BIO Investor Forum

Learn More